Biocept, inc. announces liquid biopsy ctc testing for breast cancer to be featured in poster presentation at the 2019 san antonio breast cancer symposium®

Biocept, inc. announces that clinical data supporting the use of its target selector™ ctc platform as an aid in the monitoring and treatment of breast cancer will be presented in a poster session at the 2019 san antonio breast cancer symposium® (sabcs). the symposium is being held december 10-14, at the henry b. gonzalez convention center in austin, texas. title: clinical data in over 1,500 patients across all stages of breast cancer with target selector circulating tumor cell technology; authors: veena m. singh m.d. et al.; session title: poster session 4; session date and time: december 13, 7:00 a.m. - 9:00 a.m. (edt). sabcs's mission is to provide information on breast cancer research. from a one-day regional conference, the symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries. sabcs aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
BIOC Ratings Summary
BIOC Quant Ranking